title: ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.
abstract: Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ                         (2) test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.
authors: Institute of Pathology, University Hospital Tuebingen, Tuebingen, Germany.
authors: Veit J
authors: VJ
authors: Scheble
authors: Gregor
authors: G
authors: Scharf
authors: Martin
authors: M
authors: Braun
authors: Christian
authors: C
authors: Ruiz
authors: Susanna
authors: S
authors: Stürm
authors: Karen
authors: K
authors: Petersen
authors: Rudi
authors: R
authors: Beschorner
authors: Alexander
authors: A
authors: Bachmann
authors: Tobias
authors: T
authors: Zellweger
authors: Falko
authors: F
authors: Fend
authors: Glen
authors: G
authors: Kristiansen
authors: Lukas
authors: L
authors: Bubendorf
authors: Nicolas
authors: N
authors: Wernert
authors: David
authors: D
authors: Adler
authors: Sven
authors: S
authors: Perner
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002369:Castration / Q000379:methods; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005784:Gene Amplification; D015321:Gene Rearrangement; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D011944:Receptors, Androgen / Q000235:genetics; D046888:Tissue Array Analysis; D015534:Trans-Activators / Q000235:genetics*; D000071230:Transcriptional Regulator ERG
chemical_list: D018931:Antineoplastic Agents, Hormonal; C072312:ERG protein, human; D011944:Receptors, Androgen; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG